Form 4: Vir Biotechnology Executive Sells Shares Under 10b5-1 Plan

Vir Biotechnology's EVP, General Counsel, and Corporate Secretary, Vanina de Verneuil, sold shares under pre-arranged trading plans.

Summary

• Vanina de Verneuil, EVP, General Counsel, and Corporate Secretary of Vir Biotechnology, Inc. (VIR), reported two sales of common stock.
• On February 24, 2026, 3,117 shares were sold at an average price of $9.5326 per share to satisfy tax withholding obligations related to the vesting of restricted stock units.
• On February 25, 2026, an additional 13,700 shares were sold at an average price of $9.82 per share.
• Both sales were executed pursuant to Rule 10b5-1 trading plans, with the plan for the second sale adopted on June 2, 2025.
• Following these transactions, Vanina de Verneuil directly beneficially owns 112,982 shares of Vir Biotechnology common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While it's a sale by an insider, the pre-planned nature and tax-related component mitigate concerns about negative sentiment, suggesting routine financial management rather than a lack of confidence.

Positives

• The sales were conducted under Rule 10b5-1 trading plans, indicating pre-planned transactions rather than immediate discretionary decisions based on new information.
• One sale was specifically for tax withholding obligations related to restricted stock unit vesting, which is a common and non-discretionary event for executives.

Negatives

• An executive selling a total of 16,817 shares could be perceived negatively by some investors, even if pre-planned.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that executive stock sales, particularly those executed under pre-arranged Rule 10b5-1 plans, are common in the biotechnology sector as a means for executives to manage personal finances and diversify holdings while adhering to insider trading regulations. These sales are often tied to vesting schedules of equity compensation.

Comparison to Industry Standards

• Executive sales under Rule 10b5-1 plans are standard practice across industries, including biotechnology, for managing equity compensation and avoiding accusations of insider trading.
• Companies like Amgen (AMGN) and Gilead Sciences (GILD) frequently report similar executive sales tied to vesting or pre-planned diversification strategies, indicating this is a routine event.

Stakeholder Impact

• Shareholders: May view the executive's sale as a routine event given the 10b5-1 plan and tax withholding, but some might interpret it as a slight reduction in insider alignment.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

The filing is a routine insider transaction report (Form 4) detailing pre-planned sales by an executive. These sales, particularly those for tax withholding, are common and do not typically signal a change in the company's fundamental outlook or warrant a change in investment recommendation. The transactions are expected and do not provide new information to alter a 'hold' stance.

Keywords

Vir Biotechnology, VIR, Form 4, Insider Trading, Stock Sale, Executive Compensation, Rule 10b5-1, Restricted Stock Units, Biotechnology